Mr. William Hu is a Managing Partner of Qiming Venture Partners. Currently, William co-leads Qiming's investments in the healthcare sector.
Since his joining in 2006, William has been instrumental in building Qiming's healthcare practice, having been closely involved in the development of over 60 startups, many of which have become leading players in their respective areas. He has led investments in Tigermed (SZSE:300347, SEHK:3347), APT Medical (SHSE:688617), Sanyou Medical (SHSE:688085), Tellgen (SZSE:300642), AmoyDx (SZSE:300685), Microtech Medical (SEHK:2235), Abbisko Therapeutics (SEHK:2256), Antengene (SEHK:6996), Rendu Biotechnology (SHSE:688193), CANbridge Pharmaceuticals (SEHK:1228), Aohua Endoscopy (SHSE:688212), Arrail Group (SEHK:6639), Connect Biopharma (NASDAQ:CNTB), BBI Life Sciences (SEHK:1035), Medsci (SEHK:2415), Ark Biopharmaceutical, OriCell Therapeutics, SHIP Bio, Ribox Therapeutics, VINNO, IntoCare, ET Healthcare, Health Gene Technologies, WeDoctor, Yuanxin Technology, Bang'Er Orthopedics Hospitals, ShuLan Health, etc.
William has been recognized by Forbes China Venture Capital 100 List for seven consecutive years.
William earned a Bachelor of Medicine degree from Shanghai Medical University and an MBA degree from ENPC SH Campus.
